Inhibition of phosphoenolpyruvate carboxykinase (PEPCK) gene expression by troglitazone: A peroxisome proliferator-activated receptor-γ (PPARγ)-independent, antioxidant-related mechanism

Biochemical Pharmacology

Volumn 62, Issue 8, 2001, Pages 1071-1079

  Davies, Gerald F ^a   Khandelwal, Ramji L ^a   Wu, Lingyun ^a   Juurlink, Bernhard H J ^a   Roesler, William J ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Antioxidant; Diabetes; Gluconeogenesis; Hepatocytes; Phosphoenolpyruvate carboxykinase; Thiazolidinediones; Troglitazone

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; CIGLITAZONE; DRUG METABOLITE; ENGLITAZONE; N (2 BENZOYLPHENYL) O [2 (METHYL 2 PYRIDINYLAMINO)ETHYL]TYROSINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHOENOLPYRUVATE CARBOXYKINASE (ATP); ROSIGLITAZONE; TROGLITAZONE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG ACTIVATION; DRUG BINDING; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; DRUG STRUCTURE; GENE EXPRESSION; LIVER CELL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIOXIDANTS; CHROMANS; GENE EXPRESSION; HEPATOCYTES; MALE; OXIDATIVE STRESS; PHOSPHOENOLPYRUVATE CARBOXYKINASE (ATP); RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIAZOLES; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 0035501248     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(01)00764-X     Document Type: Article

References (47)

1. Thiazolidinediones in the treatment of insulin resistance and type II diabetes
2. In vitro studies on the action of CS-045, a new antidiabetic agent
3. Mechanisms by which thiazolidinediones enhance insulin action
4. mPPARγ2: Issue-specific regulator of an adipocyte enhancer
5. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ)
6. The structure-activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones
7. Identification of high affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor γ
8. The effect of CP-68772, a thiazolidinedione derivative, on insulin sensitivity in lean and obese Zucker rats
9. A new antidiabetic agent, BRL 49653, reduces lipid availability, and improves insulin action, and glucoregulation in the rat
10. Suppression of hepatic gluconeogenesis in long-term troglitazone treated diabetic KK and C57BL/KsJ-db/db mice
11. Troglitazone inhibits expression of the phosphoenolpyruvate carboxykinase gene by an insulin-independent mechanism
12. PPARγ2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene
13. Oleic acid promotes the activation and translocation of phosphatidate phosphohydrolase from the cytosol to particulate fractions of isolated rat hepatocytes
14. Isolation and characterization of the gene coding for cytosolic phosphoenolpyruvate carboxykinase (GTP) from the rat
15. 36B4 cDNA used as an estradiol-independent mRNA control is the cDNA for human acidic ribosomal phosphoprotein PO
16. DCFH assay: Oxidation pathways for the intracellular probe 2′,7′-dichlorofluorescein
17. Low glutathione and high iron govern the susceptibility of oligodendroglial precursors to oxidative stress
18. Troglitazone, an antidiabetic agent, inhibits cholesterol biosynthesis through a mechanism independent of peroxisome proliferator-activated receptor-γ
19. A human peroxisome-proliferator-activated receptor-γ is activated by inducers of adipogenesis, including thiazolidinedione drugs
20. A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-γ reverses the diabetic phenotype of the Zucker diabetic fatty rat
21. A synthetic antagonist for the peroxisome proliferator-activated receptor γ inhibits adipocyte differentiation
22. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay
23. Fatty acid activation of peroxisome proliferator-activated receptor (PPAR)
24. 2 metabolite binds peroxisome proliferator-activated receptor γ, and promotes adipocyte differentiation
25. Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-α, -β, and -γ in the adult rat
26. Interaction of LY171,883 and other peroxisome proliferators with fatty-acid-binding protein isolated from rat liver
27. Troglitazone has a scavenging effect on reactive oxygen species
28. Acute and chronic effects of troglitazone (CS-045) on isolated rat ventricular cardiomyocytes
29. Troglitazone enhances differentiation, basal glucose uptake, and Glut1 protein levels in 3T3-L1 adipocytes
30. Troglitazone inhibits fatty acid oxidation and esterification, and gluconeogenesis in isolated hepatocytes from starved rats
31. Glucose-6-phosphatase flux in vitro is increased in type 2 diabetes
32. Effect of troglitazone (Rezulin) on fructose 2,6-bisphosphate concentration and glucose metabolism in isolated rat hepatocytes
33. Dehydroepiandrosterone suppresses the elevated hepatic glucose-6-phosphatase and fructose-1,6-bisphosphatase activities in C57BL/KsJ-db/db mice. Comparison with troglitazone
34. Glucocorticoids repress induction by thiazolidinediones, fibrates, and fatty acids of phosphoenolpyruvate carboxykinase gene expression in adipocytes
35. Antioxidant and redox regulation of gene transcription
36. Opposing actions of Fos and Jun on transcription of the phosphoenolpyruvate carboxykinase (GTP) gene. Dominant negative regulation by Fos
37. Protein glycation and oxidative stress in diabetes mellitus and ageing
38. Elevated levels of authentic plasma hydroperoxides in NIDDM
39. Influence of reduced glutathione infusion on glucose metabolism in patients with non-insulin-dependent diabetes mellitus
40. Beneficial effects of antioxidants in diabetes: Possible protection of pancreatic β-cells against glucose toxicity
41. Primary and secondary prevention of atherosclerosis: Is there a role for antioxidants?
42. Oxidant stress reduces insulin responsiveness in 3T3-L1 cells
43. Oxidative stress disrupts insulin-induced cellular redistribution of insulin receptor substrate-1 and phosphatidylinositol 3-kinase in 3T3-L1 adipocytes
44. 2
45. Oxidative stress and insulin action: Is there a relationship?
46. Antioxidant α-tocopherol ameliorates glycemic control of GK rats, a model of type 2 diabetes
47. 2-isoprostane evidence of oxidant stress in the insulin resistant, obese Zucker rat: Effects of vitamin E